Navigation Links
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
Date:2/17/2009

LONDON, Feb. 17 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria(R) (albiglutide) in men and women with type 2 diabetes. The Phase III programme will include more than 4,000 patients.

"Despite continued advances in diabetes treatment, this devastating disease continues to increase at an alarming pace worldwide. It is clear that new therapies are needed to better control type 2 diabetes and to improve people's lives," said Carlo Russo, MD., Senior Vice President, Biopharm Development, GlaxoSmithKline. "Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar, particularly when oral treatments alone may not provide an adequate response."

About the Phase III Programme

The Phase III programme for albiglutide will begin with five studies in early 2009. The objective of the programme is to demonstrate durable efficacy and cardiovascular safety of albiglutide as mono- and add-on therapy, in patients with type 2 diabetes. The primary efficacy endpoint for all studies will be the change from baseline in HbA1c compared to placebo and/or active comparators. A majority of the studies will include active comparators, including metformin, sulphonylurea, thiazolidinedione (TZD) insulin and a dipeptidyl peptidase four inhibitor (DPP IV). The study duration is expected to be two to three years and the main dose and regimen for the programme will be 30 mg weekly.

About Albiglutide and Type 2 Diabetes

Albiglutide is an investigational biological, injectable form of human GLP-1 -- a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. Normally, GLP-1 levels rise during a meal to help the body utilise and control the elevation in blood sugar levels. However, GLP-1 is rapidly degraded, resulting in its short duration of action. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced. Albiglutide is the only medication which fuses human GLP-1 to human albumin. It is designed to have an extended duration of action and allow for weekly or less-frequent injections.

Type 2 diabetes is a chronic, progressive illness often linked to premature death, and affects over 250 million individuals worldwide, nearly six percent of the world's adult population.(1) According to the Centers for Disease Control and Prevention (CDC), the incidence of newly diagnosed diabetes in the U.S. has nearly doubled in the last 10 years. (2) The International Diabetes Federation (IDF) estimates that by 2025, more than 380 million people worldwide will suffer from this disease. (3)

Diabetes occurs when the pancreas does not produce enough insulin (type 1) or when the body does not respond properly to, or produce enough, insulin (type 2). The two defects result in increased concentrations of blood sugar, which in turn damages many of the body's systems, in particular the blood vessels and nerves.(3) Complications from diabetes can include eye disease (blindness), kidney disease (kidney failure/dialysis), nerve damage (amputation), heart disease, stroke and peripheral vascular disease.(4)

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

Syncria(R) is the registered trademark to be used in the United States.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

References:

1. The International Diabetes Federation. Unite for Diabetes: Wake-up Call to Halt Global Diabetes Epidemic. Available at:

http://www.unitefordiabetes.org/assets/files/About_diabetes.pdf

2. State-specific Incidence of Diabetes Among Adults. Available at: http://www.cdc.gov/mmwr/preview .

3. International Diabetes Federation. Diabetes Prevalence. Available at: http://www.idf.org/home/index.cfm?node=264 . Accessed on July 27, 2006.

4. Available at: http://diabetes.niddk.nih.gov/dm/pubs/insulinresistance/. Accessed on January 28, 2009.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road Brentford, Middlesex TW8 9GS


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: